NDT Advance Access originally published online on September 6, 2006
Nephrology Dialysis Transplantation 2006 21(10):2893-2899; doi:10.1093/ndt/gfl393
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome
1Department of Internal Medicine, College of Medicine Yonsei University, Seoul, 2Wallace Memorial Baptist Hospital, Pusan, 3Yeungnam University, Daegu, 4Konyang University, Daejeon, 5Inje University, Pusan, 6Kyungpook National University, Daegu, 7Samsung Medical Center, Sungkyunkwan University, Seoul, 8The Catholic University, Seoul, 9Inha University, Incheon and 10National Health Insurance Corporation Ilsan Hospital, Seoul, Korea
Correspondence and offprint requests to: Ho Yung Lee, MD, Department of Internal Medicine, Yonsei University College of Medicine, CPO Box 8044, Seoul, Korea. Email: hyl{at}yumc.yonsei.ac.kr
Background. Novel, biocompatible peritoneal dialysis (PD) solutions have become available in recent years. In 2001, low glucose degradation products (GDP), neutral pH solutions became commercially available in Korea. To date, there are no reports regarding the large scale adoption of these solutions in clinical practice and regarding what, if any, impact these solutions have on patient outcomes.
Methods. Using a database of almost 4000 patients treated by PD in Korea, we conducted a prospective, longitudinal observational study documenting the patterns of use of one novel low GDP solution (balance®, Fresenius Medical Care, St Wendel, Germany) in 1909 PD incident patients between 1 January 2002 and midyear 2005. Outcomes including patient and technique survival and peritonitis rates were analysed using univariate and multivariate analysis.
Results. Prescription of low GDP solutions reached between 70 and 80% by the year 2003 and persisted at this level. Patients prescribed low GDP PD solution tended to be younger and were more likely to be treated in centres with larger enrolment in the database. Survival of diabetic patients treated with the new PD solution was identical to that of the non-diabetic patients treated with standard PD fluids (PDF) and treatment with low GDP PDF independently reduced the relative risk (RR) of death (RR = 0.613; CI 0.50–0.74; P < 0.00001) in a proportional hazards model which included age, diabetes and centre experience. In a univariate analysis, low GDP PD solution was associated with a longer technique survival (P = 0.049) but this effect was not significant in multivariate analysis. No significant differences in peritonitis-free interval or peritonitis rate could be attributed to the prescribed PDF.
Conclusion. Prescription of low GDP, pH-neutral PD solutions has rapidly increased in Korea. This change has resulted in a significant improvement in patient and technique survival without any measurable change in peritonitis incidence or rate. Reasons for the improved patient survival cannot be determined from this analysis and require further study.
Keywords: CAPD; glucose degradation products; patient survival; pH neutral; prescribing practices
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in NDT:
- Peritoneal dialysis solutions and patient survival: does wishing make it so?
- Joanne M. Bargman
NDT 2006 21: 2684-2686.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  M. Erixon, A. Wieslander, T. Linden, O. Carlsson, J. A. Jonsson, O. Simonsen, and P. Kjellstrand 3,4-DIDEOXYGLUCOSONE-3-ENE IN PERITONEAL DIALYSIS FLUIDS INFUSED INTO THE PERITONEAL CAVITY CANNOT BE FOUND IN PLASMA Perit. Dial. Int., February 1, 2009; 29(Supplement_2): S28 - S31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nakayama, M. Nakayama, H. Terawaki, T. Satoh, M. Kohno, and S. Ito {alpha}-Oxoaldehydes in haemodialysis solution Nephrol. Dial. Transplant., July 1, 2007; 22(7): 2097 - 2098. [Full Text] [PDF]
|
|
|
|
|
|
Y.-L. Kim CAN WE OVERCOME THE PREDESTINED POOR SURVIVAL OF DIABETIC PATIENTS? PERSPECTIVES FROM PRE- AND POST-DIALYSIS Perit. Dial. Int., June 1, 2007; 27(Supplement_2): S171 - S175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Stinghen, P. Barretti, and R. Pecoits-Filho FACTORS CONTRIBUTING TO THE DIFFERENCES IN PERITONITIS RATES BETWEEN CENTERS AND REGIONS Perit. Dial. Int., June 1, 2007; 27(Supplement_2): S281 - S285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Bargman New Technologies in Peritoneal Dialysis Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 576 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Bargman Peritoneal dialysis solutions and patient survival: does wishing make it so? Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2684 - 2686. [Full Text] [PDF]
|
|